香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：2268） 於2025年12月12日舉行的股東特別大會之投票表決結果 董事會宣佈，於2025年12月12日舉行的股東特別大會上，股東特別大會通知中 所載的所有提呈決議案獲本公司股東以投票表決方式正式通過。 藥 明 合 聯 生 物 技 術 有 限 公 司 *（「 本 公 司 」）董 事（「 董 事 」）會（「 董 事 會 」）宣 佈 ， 於 2025年12月12日舉行之本公司股東特別大會（「股東特別大會」）上，股東特別大會 通知中所載的所有提呈決議案獲本公司股東以投票表決方式正式通過。除另有界 定外，本公告所用詞彙與日期為2025年11月26日的通函（「通函」）所界定者具有相 同涵義。執行董事李錦才博士、張靖偉先生及席曉捷先生；以及非執行董事陳智 勝博士親身或以電子方式出席股東特別大會。 – 1 ...

港股收盘，恒生指数涨1.75%，恒生科技指数涨1.87%。港股科技ETF（159751）涨1.42%，恒生港股通 ETF（159318）涨1.67%。板块方面，电气设备、生命科学工具板块涨幅靠前；居家用品、航空货运与 物流板块跌幅靠前。个股方面，中国银河涨9.45%，广发证券涨7.33%，康方生物涨7.33%，农夫山泉涨 7.23%，网易-S涨6.87%，交通银行涨6.57%，中信证券涨6.42%，国泰海通涨5.99%，中国财险涨 5.91%，新鸿基地产涨5.79%，百济神州涨5.64%，华泰证券涨5.63%，科伦博泰生物-B涨5.6%，中国太 保涨5.13%，长实集团涨5.05%，中国人寿涨5.0%，长江基建集团涨4.64%，中国铝业涨4.58%，五矿资 源涨4.55%，中兴通讯涨4.51%，中通快递-W涨4.05%；药明合联跌8.36%，曹操出行跌11.11%；昭衍新 药涨19.41%，狮腾控股涨14.55%。 ...

该行继续推荐关注以下细分方向：1)创新药：三生制药(01530)、德琪医药-B(06996)、百济神州(06160) 等催化剂丰富、估值仍未反映核心大单品价值;先声药业(02096)、传奇生物被明显低估、长期成长逻辑 清晰;2)CXO：受益于下游高景气度和融资边际回暖的细分赛道龙头，如药明合联(02268);3)监管不确定 性逐步释放，有反转机会的医院、器械和诊断等子板块。 智通财经APP获悉，交银国际发布研报称，本周医保+商保双目录落地，医保谈判新增品种成功率创近 年新高，续约品种降价幅度相对温和。该行认为，商保资金的引入将为创新药支付带来重要增量资金， 进一步优化多元支付体系。该行看好医保新纳入品种/适应症在2026年的销售放量，以及首版商保目录 的实际执行和支付情况。 ...

Group 1 - The stocks of Zhaoyan New Drug (06127.HK) increased by 5.54% [1] - Rongchang Biologics (09995.HK) saw a rise of 3.95% [1] - WuXi AppTec (02268.HK) experienced a growth of 3.05% [1] - Cornerstone Biosciences-B (02616.HK) rose by 2.86% [1]

Investment Rating - The report rates the pharmaceutical and biotechnology industry as "Outperforming the Market" [1][8]. Core Insights - The report highlights a significant increase in the success rate of negotiations for high-value innovative drugs, with the 2025 National Medical Insurance Directory adding 114 new drugs, including 50 innovative drugs, and achieving a negotiation success rate of 88%, up from 76% in 2024 [3]. - The introduction of a commercial insurance drug directory marks a new phase in healthcare, aiming to create a multi-layered insurance system that complements basic medical insurance, with 19 innovative drugs included in the first version [3]. - The report emphasizes the potential for Chinese innovative drugs to expand internationally, with a focus on ADCs, bispecific antibodies, small nucleic acids, and weight-loss drugs as key investment opportunities [3]. Summary by Sections Industry Performance - The SW Pharmaceutical and Biotechnology Index decreased by 0.74% in the week of December 1-7, underperforming the Shanghai and Shenzhen 300 Index, which increased by 1.28% [2]. - Within the pharmaceutical sector, the drug distribution (+6.48%) and offline pharmacy (+1.85%) segments performed relatively well, while raw materials (-2.54%), vaccines (-1.62%), and CXO (-1.29%) segments showed weaker performance [2]. National Medical Insurance Directory - The 2025 version of the National Medical Insurance Directory will officially implement on January 1, 2026, with a total of 3,253 drugs included, enhancing coverage for critical areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [3]. - Notably, 105 of the newly added drugs are exclusive products, including 98 Western medicines and 7 traditional Chinese medicines [3]. Commercial Insurance Drug Directory - The first version of the commercial insurance innovative drug directory includes 19 drugs, focusing on high clinical value and significant patient benefits, which are beyond the scope of basic medical insurance [5]. - This directory includes treatments for rare diseases, cancer therapies, and Alzheimer's disease, establishing a foundation for the development of a multi-tiered medical insurance system [3][5]. Investment Recommendations - The report suggests a positive outlook for the international expansion of Chinese innovative drugs and recommends monitoring ADCs, bispecific antibodies, small nucleic acids, and weight-loss drugs for investment opportunities [3]. - Key companies to watch include Yiming Biotechnology-B, WuXi AppTec, Maiwei Biotechnology-U, Kelun-Biotech, and Kangfang Biotech [3].

港股创新药概念走强，歌礼制药一度飙涨超20%，药明合联、药明生物、恒瑞医药等跟涨。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 √ | | --- | --- | --- | --- | --- | | 01672 | 歌礼制药-B ● | 17.140 | +2.810 | 19.61% | | 02268 | 药明合联 | 69.700 | +2.350 | 3.49% | | 02269 | 药明生物 | 33.740 | +0.800 | 2.43% | | 01276 | 恒瑞医药 | 74.100 | +1.550 | 2.14% | | 00867 | 康哲药业 | 13.870 | +0.210 | 1.54% | | 01177 | 中国生物制药 | 6.850 | +0.070 | 1.03% | | 02096 | 先声药业 | 13.850 | +0.140 | 102% | 此番大涨背后，直接催化因素是歌礼制药昨晚公布的一项重磅临床研究结果。 研究显示，口服小分子 GLP-1药物ASC30在肥胖或超重受试者中进行的美国13周II期研究显示经安慰剂校正后的体重下降达 7.7 ...

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [2][29]. Core Insights - The release of the 2025 version of the basic medical insurance directory continues to support innovation, with 114 new drugs added, including 50 first-class innovative drugs, while 29 drugs were removed due to lack of supply or better alternatives [3]. - The MSCI China Healthcare Index has seen a cumulative increase of 60.9% since the beginning of 2025, outperforming the MSCI China Index by 29.2% [1]. - Despite a recent 9% pullback in the healthcare sector, undervalued stocks present attractive investment opportunities [1][3]. - The trend of innovative drugs going overseas is expected to continue, with a focus on the progress of these products in international markets [1]. - The demand for innovative drug research and development in China is showing signs of recovery, supported by a resurgence in capital market financing and an increase in the scale of overseas transactions [1]. Summary by Sections Industry Research - The report highlights that the adjustment of the medical insurance directory emphasizes support for "true innovation" and "differentiated innovation" [3]. - The first version of the commercial insurance directory includes 19 innovative drugs, which may pave the way for the expansion of commercial medical insurance in China [3]. - The report recommends a more cautious investment approach, focusing on undervalued stocks in the sector [3]. Company Ratings - Recommended companies include: - 三生制药 (Sangfor) with a target price of 37.58 and a potential upside of 29% [2]. - 固生堂 (Gushengtang) with a target price of 44.95 and a potential upside of 58% [2]. - 药明合联 (WuXi AppTec) with a target price of 74.00 and a potential upside of 10% [2]. - 巨子生物 (Giant Biotech) with a target price of 53.89 and a potential upside of 48% [2]. - 信达生物 (Innovent Biologics) with a target price of 110.62 and a potential upside of 29% [2]. - 中国生物制药 (China National Pharmaceutical Group) with a target price of 9.40 and a potential upside of 39% [2].

Macro Economic Overview - China's exports showed a short-term rebound in November, exceeding market expectations, driven by improvements in exports to the EU, Latin America, Japan, South Korea, and Africa, while exports to the US and ASEAN remained weak [2] - The semiconductor exports benefited from the global AI boom, maintaining a high growth rate, reflecting China's ongoing technological advancements [2] - Imports slightly improved due to processing trade, but general trade continued to decline due to weak domestic demand [2] Global Market Performance - The Hang Seng Index closed at 25,765, down 1.23% for the day but up 28.44% year-to-date [3] - The Shanghai Composite Index rose 0.54% to 3,924, with a year-to-date increase of 17.08% [3] - The US markets saw a decline, with the Dow Jones down 0.45% and the S&P 500 down 0.35% [3] Automotive Industry Insights - The Chinese automotive industry is expected to see retail and wholesale sales reach historical highs in 2025, with a more complex landscape anticipated in 2026 due to the phasing out of subsidies [6][7] - Despite challenges from subsidy reductions, retail sales are expected to remain stable, with wholesale volumes projected to grow by 2.9% in 2026 [7] - The competition in the automotive sector is expected to intensify, with new model releases at historical highs and potential price increases in battery costs impacting profit margins [7] Insurance Sector Analysis - The recent adjustment in risk factors for insurance companies aims to encourage long-term equity holdings, potentially releasing a minimum capital of 30.8 billion yuan [9][10] - The adjustment is expected to enhance the capital efficiency of insurance investments in A-shares compared to H-shares, benefiting major players like China Ping An and China Life [11] - The insurance sector maintains a "buy" rating, with recommended stocks including China Ping An, China Life, and AIA Group [12] Pharmaceutical Industry Developments - The MSCI China Healthcare Index has risen by 60.9% year-to-date, outperforming the MSCI China Index [13] - The recent release of the basic medical insurance directory supports innovation, with 114 new drugs added, including 50 innovative drugs [13][14] - The commercial insurance directory's introduction is seen as a significant step towards expanding China's commercial health insurance landscape [14][15]

Group 1 - The three major indices opened lower on December 9, with the Hang Seng Shanghai Shenzhen Hong Kong Innovative Drug Selected 50 Index (HSSSHID.HK) rising over 1%, driven by significant gains in stocks like Zhaoyan New Drug and WuXi AppTec, which both increased by over 10% [1] - The Tianhong Innovative Drug ETF (517380) showed strength with a real-time premium rate of 0.17%, and it recorded a net inflow of 15.58 million yuan on the previous trading day, marking eight consecutive days of net inflows totaling 113 million yuan [1] - The new National Medical Insurance Drug List, effective from January 1, 2026, adds 114 new drugs, including 50 Class 1 innovative drugs, while removing 29 drugs that are either not clinically available or can be replaced by better alternatives, increasing the total number of drugs in the list to 3,253 [1] Group 2 - The Tianhong Innovative Drug ETF tracks the Hang Seng Hong Kong-Shenzhen Innovative Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization, allowing for investment in both A-share and Hong Kong stocks in innovative drugs and CXO leading enterprises [2] - CITIC Securities believes that the success rate of national medical insurance negotiations is at a record high, and the commercial insurance directory is expected to become an important growth driver, with policies encouraging the development of innovative drugs [2] - The international competitiveness of China's innovative drug pipeline continues to improve, with ongoing upgrades in overseas expansion models and new technologies driving rapid industry development [2]

Core Viewpoint - The release of the 2025 version of the basic medical insurance directory and the first commercial insurance directory is expected to support innovation in the CXO industry, leading to a potential performance recovery in the second half of the year [1] Summary by Categories Industry Outlook - The report indicates that several companies' core innovative products have been included in the medical insurance directory [1] - Despite ongoing pressures on medical insurance revenue due to macroeconomic conditions and aging populations, attention is drawn to the renewal of national centralized procurement [1] Commercial Insurance - The initial commercial insurance directory is expected to have limited short-term impact on product sales due to the small scale of commercial insurance [1] - However, the significance of the commercial insurance directory is highlighted as it may pave the way for the expansion of commercial medical insurance in China, marking the beginning of a diversified payment system development [1] Company Recommendations - The report recommends buying shares in the following companies: - Sanofi (01530) - Genscript Biotech (02273) - WuXi AppTec (02268) - Genor Biopharma (02367) - Innovent Biologics (01801) - China Biologic Products (01177) [1]